A phase I clinical trial of sequentially administered doxorubicin and topotecan in refractory solid tumors.

PURPOSE To determine whether agents that target topoisomerase I and II could be administered sequentially. DESIGN A Phase I study was conducted to evaluate sequential treatment with bolus IV doxorubicin followed 48 h later by topotecan given as a 30-min i.v. infusion on 3 consecutive days, with additional cycles of therapy repeated every 3 weeks… (More)